胸腹主动脉瘤开窗/分支腔内修复术后1年瘤囊回缩与长期生存改善相关
本研究为单中心回顾性队列,纳入68例胸腹主动脉瘤行开窗/分支腔内修复且1年有CTA的患者,按瘤囊变化分为回缩(≥5mm缩小)、稳定(±5mm)和增长(≥5mm增大),稳定与增长合并为未回缩。中位随访56.5个月,未回缩与全因死亡率升高独立相关(多变量HR 2.55,95%CI 1.14-5.71;P=0.023),且晚期再干预率更高(HR 3.03,95%CI 1.09-8.37;P=0.033)。
要点
- f/bEVAR术后1年瘤囊未回缩与长期全因死亡率升高独立相关。
- 未回缩患者晚期再干预需求更高,但再干预未增加死亡风险。
- 1年CTA瘤囊动态可用于风险分层,指导个体化随访。
核心结论
- 胸腹主动脉瘤f/bEVAR术后1年瘤囊未回缩与更差长期生存和更高再干预率相关。
- 1年CTA瘤囊动态对不良结局有预测价值,可用于风险分层。
研究设计与样本
- 回顾性单中心队列研究,纳入2006年4月至2025年3月间行f/bEVAR的胸腹主动脉瘤患者。
- 共68例符合纳入标准,均于术后1年行CTA评估瘤囊直径变化。
主要发现
- 1年瘤囊回缩24例(35.3%),未回缩44例(64.7%),其中稳定35例(51.5%)、增长9例(13.2%)。
- 中位随访56.5个月,总死亡率为55.9%(38例)。
- 未回缩与全因死亡率升高相关:单变量HR 2.78(95%CI 1.33-5.81;P=0.007),多变量HR 2.55(95%CI 1.14-5.71;P=0.023)。
- 未回缩与晚期I/III型内漏无显著关联(HR 1.50,95%CI 0.48-4.64;P=0.48)。
- 未回缩患者晚期再干预需求更高(HR 3.03,95%CI 1.09-8.37;P=0.033),但再干预未增加死亡风险(HR 0.95,95%CI 0.48-1.90;P=0.89)。
关键数值与推荐
- 瘤囊变化定义:回缩为直径缩小≥5mm,稳定为变化±5mm,增长为增大≥5mm。
- 稳定与增长合并为未回缩(失败回缩)。
- 所有晚期再干预均为经皮方式:主体再衬/延伸5例,桥接支架相关14例,弹簧圈栓塞2例。
临床怎么用
- f/bEVAR术后1年CTA评估瘤囊回缩情况,未回缩者应加强随访和再干预评估。
- 瘤囊未回缩可作为风险分层工具,指导个体化治疗和监测方案。
局限性
- 回顾性单中心研究,样本量较小(68例)。
- 仅纳入1年时行CTA的患者,可能存在选择偏倚。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: This study evaluated the association between sac regression at 1 year and long-term outcomes after fenestrated and branched endovascular aortic repair (f/bEVAR) for thoracoabdominal aortic aneurysm (TAAA). METHODS: A retrospective single-center cohort study was conducted of patients who underwent f/bEVAR for TAAA between April 2006 and March 2025 and had computed tomography angiography (CTA) at 1 year. Sac diameter change was categorized as regression (≥5 mm decrease), stable (±5 mm change), or growth (≥5 mm increase). Stable and growth were combined as failure to regress. The primary outcome was all-cause mortality. Secondary outcomes included late type I/III endoleaks and late reintervention. Kaplan-Meier analysis and Cox models were used. RESULTS: Sixty eight patients met inclusion criteria. Sac regression 1 year after f/bEVAR occurred in 24 patients (35.3%), whereas 44 (64.7%) demonstrated failure to regress (35 stable, 51.5%; nine growths, 13.2%). Median age was 67.5 years (interquartile range [IQR] 65.0-74.8) and 74.0 years (IQR 68.0-76.8), and 12 (50.0%) and 32 (72.7%) patients were male for the aneurysm regression and failure to regress groups, respectively. During a median follow-up of 56.5 months, overall mortality was 55.9% (38 patients). In a univariable model, failure to regress was significantly associated with higher all-cause mortality (hazard ratio [HR] 2.78, 95% confidence interval [CI] 1.33-5.81; P = 0.007). This association was confirmed in multivariable analysis (HR 2.55, 95% CI 1.14-5.71; P = 0.023). Although there was no association between failure to regress and late type I or III endoleak (HR 1.50, 95% CI 0.48-4.64: P = 0.48), the need for late reintervention was higher for patients with failure to regress (HR 3.03, 95% CI 1.09-8.37; P = 0.033). Notably, all late reinterventions were percutaneous (five main body relinings/extensions; 14 bridging stent-related; two coiling procedures) and did not increase mortality risk (HR 0.95, 95% CI 0.48-1.90; P = 0.89). CONCLUSION: Aneurysm sac failure to regress at 1 year after f/bEVAR for TAAA is associated with worse long-term survival and increased reintervention rate. The predictive value of aneurysm sac dynamics at 1 year CTA, for adverse outcomes highlights its potential for risk stratification, guiding patient specific treatment regimen.
引用
- Huistra EWM, Tielliu IFJ, Gareb B, et al. Aneurysm Sac Regression after Fenestrated and Branched Endovascular Repair for Thoracoabdominal Aortic Aneurysms Is Associated with Improved Long-Term Survival. Ann Vasc Surg. 2026. PMID: 42562223. doi:10.1016/j.avsg.2026.07.047
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。